Month: August 2021

– Update on FDA Inspection of Buena Facility– Assessing New Growth Opportunities in Injectables– Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time – Dial in:  (877) 407-0792 US Toll Free Number    (201) 689-8263 International Number    Confirmation Number: 13721972BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) — Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. “Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest generic pricing erosion seen within the topicals segment,” said Tim Sawyer, Teligent’s President & Chief Executive...

Record Quarterly Revenue of $146 Million, an Increase of 53.3% Year-Over-Year June and July are the Highest Consecutive Production Months in the Company’s History Announces Americas Oat Base Capacity Expansion to Support an Acceleration in Consumer Demand Company Provides Full Fiscal Year 2021 Outlook, Anticipates Revenue to Exceed $690 Million MALMÖ, Sweden, Aug. 16, 2021 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world’s original and largest oat drink company, today announced financial results for the second quarter and six months ended June 30, 2021. Toni Petersson, Oatly’s CEO, commented, “2021 represents the most transformational year in our Company’s history with the completion of our successful IPO in May, which has provided us with the capital to fuel new production capacity globally...

Ecoark expects to exceed previously issued full-year guidance for fiscal 2022 SAN ANTONIO, Aug. 16, 2021 (GLOBE NEWSWIRE) — Ecoark Holdings, Inc. (“Ecoark”) (NASDAQ: ZEST), today announced the following operating results for the first quarter of fiscal 2022 ended June 30, 2021.Achieved revenue of $6.9 million, reflecting an approximately three-fold increase compared to $2.3 million in the prior year period Generated gross profit of $2.9 million, up from $1.2 million in the prior year period and reflecting gross margins of 42% Reported net income of $2.6 million, or $0.112 per basic and $0.097 per diluted share versus a net loss of $21.2 million or $1.154 loss per basic and diluted share in the prior year period. The net income for the first quarter of fiscal 2022 resulted from a non-cash gain of approximately $5.0 million due...

CALGARY, Alberta, Aug. 16, 2021 (GLOBE NEWSWIRE) — Questor Technology Inc. (“Questor” or the “Company”) (TSX-V: QST) announced today its financial and operating results for the second quarter 2021.   SECOND QUARTER 2021 FINANCIAL RESULTS (Unaudited, stated in Canadian dollars except per share and unit data)For the Three months ended June 30, Six months ended June 30,2021 2020 2021 2020  ($) ($) ($) ($)         Revenue 1,184,040 1,030,724 2,732,431 5,520,194Gross profit (loss) (127,077) (36,817) (91,252) 1,950,129Profit (loss) for the period (873,214) (1,247,510) (1,759,101) 17,942Gross profit (loss) as a percent of revenue (11)% (4)% (3)% 35%Net cash generated (used) by operating activities (56,208) 374,415 (779,903) 1,735,205         Earnings (Loss) per share    Basic $(0.03) $(0.05) $(0.06) $0.00Diluted $(0.03) $(0.05) $(0.06) $0.00              As...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRES OR OTHER DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 16, 2021 (GLOBE NEWSWIRE) —  Ceres Acquisition Corp. (NEO: CERE.U, CERE.WT; OTCQX: CERAF) (“Ceres” or the “Corporation”) is reporting its financial results as at June 30, 2021, and for the three and six month periods then ended. The Corporation’s unaudited financial statements, along with the accompanying management’s discussion and analysis, have been filed on the System for Electronic Document Analysis and Retrieval (SEDAR) and may be viewed by interested parties under the Corporation’s profile at www.sedar.com. As previously announced, on February 21, 2021, Ceres entered into a definitive business combination agreement with SH Parent, Inc. (“Parallel”), one of the largest privately-held multi-state cannabis operators in the United...

On track for three programs in the clinic by year end; trial site initiation for FLT180a for Hemophilia B and FLT201 for Gaucher disease Type 1 expected by year end; program for FLT190 for Fabry disease progressing Completed first dose cohort for FLT190 Phase 1/2 dose-finding trial and advancing to next dose level; data presented by year end Updated durability data from FLT180a Phase 1/2 dose-finding trial presented by year end Defined Company strategic priorities to accelerate value creation; near-term efficiencies extend cash runway into first quarter of 2023 LONDON, Aug. 16, 2021 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating...